You need to have StyleSheet (CSS) enabled to browse this site.


In 1986, through research collaboration with BMG, Gunze obtained approval from Ministry of Health and Welfare for producing the first domestically produced bio-absorbable surgical sutures. This triggered production by BMG of medical-use polymer (PGA) materials for surgical sutures, for the first time domestically.
Thereafter, BMG had stepped forward to PGA production in larger quantities and also had been actively engaged in development and production of various types of biodegradable polymer materials:
In 1996, production of Poly-L-lactide (PLLA) materials for biodegradable and absorbable bone fixtures was commenced;
In 1997, production of Poly(L-lactide-co-ε-caprolactone) (LCL) materials for biodegradable and absorbable monofilament surgical sutures was commenced.

Making use of own advanced professional techniques in medical-use polymers, BMG not only supplies various types of biomaterials but also is engaged in developing a broad range of medical devices including dental one.

BMG has been engaged in development of advanced medical technologies through long-term close research collaboration with Institute for Frontier Medical Sciences, Kyoto University, contributing to our keeping higher advanced techniques and the lead in biopolymer suppliers. BMG will keep carrying on pioneering works to contribute to progress of the world’s medical technologies.
›› Detail of Research & Development
BMG Inc. has been aiming at higher-level quality management in accordance with global standards. Our quality assurance department has been engaged in improving and enhancing the quality management/assurance system. In March 2007, we successfully obtained ISO 13485 typically given to medical device companies satisfying global standard requirements.
Medical Devices Quality Management Systems
Requirements for regulatory purposes
45 Minamimatsunoki-cho, Higashikujo,
Minami-ku, Kyoto 601-8023, JAPAN

